NM_015102.5:c.3181G>A

Variant summary

Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PM2BP4_StrongBS1_Supporting

The NM_015102.5(NPHP4):​c.3181G>A​(p.Val1061Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000184 in 1,585,582 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V1061F) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.00052 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00015 ( 0 hom. )

Consequence

NPHP4
NM_015102.5 missense

Scores

1
18

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts U:7

Conservation

PhyloP100: -0.126
Variant links:
Genes affected
NPHP4 (HGNC:19104): (nephrocystin 4) This gene encodes a protein involved in renal tubular development and function. This protein interacts with nephrocystin, and belongs to a multifunctional complex that is localized to actin- and microtubule-based structures. Mutations in this gene are associated with nephronophthisis type 4, a renal disease, and with Senior-Loken syndrome type 4, a combination of nephronophthisis and retinitis pigmentosa. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2014]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_benign. Variant got -3 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.012656927).
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.000519 (79/152250) while in subpopulation AFR AF= 0.00161 (67/41548). AF 95% confidence interval is 0.0013. There are 0 homozygotes in gnomad4. There are 42 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
NPHP4NM_015102.5 linkc.3181G>A p.Val1061Ile missense_variant Exon 22 of 30 ENST00000378156.9 NP_055917.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
NPHP4ENST00000378156.9 linkc.3181G>A p.Val1061Ile missense_variant Exon 22 of 30 1 NM_015102.5 ENSP00000367398.4 O75161-1
NPHP4ENST00000378169.7 linkn.*2082G>A non_coding_transcript_exon_variant Exon 19 of 27 1 ENSP00000367411.3 D6RA06
NPHP4ENST00000489180.6 linkn.*992G>A non_coding_transcript_exon_variant Exon 25 of 33 2 ENSP00000423747.1 O75161-2
NPHP4ENST00000378169.7 linkn.*2082G>A 3_prime_UTR_variant Exon 19 of 27 1 ENSP00000367411.3 D6RA06
NPHP4ENST00000489180.6 linkn.*992G>A 3_prime_UTR_variant Exon 25 of 33 2 ENSP00000423747.1 O75161-2

Frequencies

GnomAD3 genomes
AF:
0.000519
AC:
79
AN:
152132
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00162
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0000654
Gnomad ASJ
AF:
0.000288
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000415
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000118
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.000140
AC:
29
AN:
207022
Hom.:
0
AF XY:
0.000178
AC XY:
20
AN XY:
112260
show subpopulations
Gnomad AFR exome
AF:
0.000611
Gnomad AMR exome
AF:
0.0000664
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.0000667
Gnomad SAS exome
AF:
0.000271
Gnomad FIN exome
AF:
0.0000543
Gnomad NFE exome
AF:
0.000109
Gnomad OTH exome
AF:
0.000191
GnomAD4 exome
AF:
0.000148
AC:
212
AN:
1433332
Hom.:
0
Cov.:
34
AF XY:
0.000130
AC XY:
92
AN XY:
709958
show subpopulations
Gnomad4 AFR exome
AF:
0.00183
Gnomad4 AMR exome
AF:
0.0000733
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.0000784
Gnomad4 SAS exome
AF:
0.000171
Gnomad4 FIN exome
AF:
0.0000392
Gnomad4 NFE exome
AF:
0.000100
Gnomad4 OTH exome
AF:
0.000304
GnomAD4 genome
AF:
0.000519
AC:
79
AN:
152250
Hom.:
0
Cov.:
32
AF XY:
0.000564
AC XY:
42
AN XY:
74464
show subpopulations
Gnomad4 AFR
AF:
0.00161
Gnomad4 AMR
AF:
0.0000654
Gnomad4 ASJ
AF:
0.000288
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.000415
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000118
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.000311
Hom.:
0
Bravo
AF:
0.000499
TwinsUK
AF:
0.000270
AC:
1
ALSPAC
AF:
0.00
AC:
0
ESP6500AA
AF:
0.000944
AC:
4
ESP6500EA
AF:
0.00
AC:
0
ExAC
AF:
0.000191
AC:
23

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Uncertain:2
Aug 15, 2018
Eurofins Ntd Llc (ga)
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Oct 04, 2022
Mayo Clinic Laboratories, Mayo Clinic
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not specified Uncertain:1
May 10, 2022
Genetic Services Laboratory, University of Chicago
Significance: Uncertain significance
Review Status: no assertion criteria provided
Collection Method: clinical testing

DNA sequence analysis of the NPHP4 gene demonstrated a sequence change, c.3181G>A, in exon 22 that results in an amino acid change, p.Val1061Ile. This sequence change has been described in the gnomAD database with a frequency of 0.10% in the African/African American subpopulation (dbSNP rs143020939). The p.Val1061Ile change affects a poorly conserved amino acid residue located in a domain of the NPHP4 protein that is not known to be functional. The p.Val1061Ile substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). This sequence change does not appear to have been previously described in individuals with NPHP4-related disorders. Due to insufficient evidences and the lack of functional studies, the clinical significance of the p.Val1061Ile change remains unknown at this time. -

Senior-Loken syndrome 4 Uncertain:1
Sep 28, 2017
Illumina Laboratory Services, Illumina
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. -

Senior-Loken syndrome 4;C1847013:Nephronophthisis 4 Uncertain:1
Oct 31, 2018
Fulgent Genetics, Fulgent Genetics
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Nephronophthisis Uncertain:1
Nov 27, 2023
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 1061 of the NPHP4 protein (p.Val1061Ile). This variant is present in population databases (rs143020939, gnomAD 0.1%). This variant has not been reported in the literature in individuals affected with NPHP4-related conditions. ClinVar contains an entry for this variant (Variation ID: 167372). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt NPHP4 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Nephronophthisis 4 Uncertain:1
Sep 28, 2017
Illumina Laboratory Services, Illumina
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.061
BayesDel_addAF
Benign
-0.29
T
BayesDel_noAF
Benign
-0.21
CADD
Benign
0.077
DANN
Benign
0.69
DEOGEN2
Benign
0.088
T
Eigen
Benign
-1.7
Eigen_PC
Benign
-1.5
FATHMM_MKL
Benign
0.12
N
LIST_S2
Benign
0.60
T
M_CAP
Benign
0.014
T
MetaRNN
Benign
0.013
T
MetaSVM
Benign
-0.93
T
MutationAssessor
Benign
-0.71
N
PrimateAI
Benign
0.28
T
PROVEAN
Benign
0.19
N
REVEL
Uncertain
0.40
Sift
Benign
1.0
T
Sift4G
Benign
1.0
T
Polyphen
0.0040
B
Vest4
0.14
MVP
0.37
MPC
0.054
ClinPred
0.0040
T
GERP RS
-5.5
Varity_R
0.012
gMVP
0.23

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs143020939; hg19: chr1-5934581; API